Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease

Frontiers in Medicine

article

Jack S. Cornish¹  Elisa Wirthgen²  Jan Däbritz³ 

[1] University Hospital Geelong, Barwon Health;Department of Pediatrics, Rostock University Medical Center;Center for Immunobiology, The Barts and the London School of Medicine and Dentistry, Blizard Institute, Barts Cancer Institute, Queen Mary University, United Kingdom

关键词: intestinal inflammation;    outcome;    predictors;    Crohn's disease;    ulcerative colitis;    thiopurine;    azathioprine;    6-mercaptopurine;   

DOI  :  10.3389/fmed.2020.00008

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

The complex nature of inflammatory bowel disease (IBD) often results in treatment failure for many patients. With some patients cycling through multiple therapies before achieving a sustained period of remission, the ability to predict a patient's response to therapeutics could decrease the time from active disease to clinical remission and mucosal healing. The prospect of such individualized treatment of IBD would be aided by accurate biomarkers, both fecal and serological, which have to date shown value as indicators of IBD activity. Here we review the utility of generic biomarkers for inflammation or mucosal healing, such as calprotectin, C-reactive protein (CRP), and fecal hemoglobin (fHb) as predictors of response to treatment of IBD. We further provide a deeper insight into the utility of monitoring the thiopurine treatment by thiopurine metabolites or alternative hematologic parameters. In light of multiple recent publications of biomarkers and biological therapy, our focus in this review is predicting response to thiopurine treatment only, that is, Azathioprine and 6-Mercaptopurine.

【 授权许可】

CC BY